|
| Author [ref.] | Journal | Year | Type of cancer | No. of samples | Methods | Positive rate (%) | Significances |
|
| Chen et al. [25] | Cancer Immunol Immunother | 2011 | Esophageal squamous cell carcinoma | 112 | IHC | 95.5% | Correlation with gender, distant metastasis, TNM stage; reverse correlation with densities of CD3+ and CD8+ T cells, and survival |
|
| Jung et al. [26] | Korean J Urol | 2011 | Renal cell carcinoma | 102 | IHC | 17.6% (early-stage T1) | No correlation with age, gender, TNM stage, lymphovascular invasion or nuclear grade; correlation with recurrence; reverse correlation with survival |
|
| Quandt et al. [6] | Clin Cancer Res | 2011 | Melanoma | 29 | IHC | 96.6% (primary), 89.7% (metastatic) | Reverse correlation with survival; no correlation with CD8+ T-cell infiltration |
|
| Arigami et al. [7] | J Surg Oncol | 2010 | Gastric cancer | 94 | RT-PCR | 75.5% | Reverse correlation with survival |
|
| Jiang et al. [27] | Cancer Immunol Immunother | 2010 | Gastric cancer | 156 | IHC | 44.9% | Reverse correlation with survival |
|
| Anderson et al. [28] | J Natl Cancer Inst | 2010 | Ovarian cancer | 34 | ELISA | — | No correlation with diagnosis markers |
|
| Qian et al. [30] | Clin Exp Med | 2010 | 11 types of cancer* | 289 | IHC | Overall 52.9% (details refer to the article) | Correlation with stages |
|
| Yee et al. [40] | Histopathology | 2010 | Brenner tumor | 34 | IHC | 100% | Higher proportion of expression than CA-125 and CEA |
|
Oikonomopoulou
et al. [29] | Br J Cancer | 2008 | Ovarian cancer | 98 | ELISA | — | Useful in predicting short-term (1-year) survival, time to progression after chemotherapy |
|
| Awadallah et al. [31] | Pancreas | 2008 | Pancreatic ductal adenocarcinoma | 36 | IHC | 91.7% | More powerful than p53; potential diagnostic use |
|
| Thompson RH et al. [39] | Cancer Res | 2008 | Renal cell carcinoma | 101 | ELISA | 52.5% | Correlation with stage; a potential serum marker for diagnosis and prognosis |
|
| Mugler et al. [32] | Appl Immunohistochem Mol Morphol | 2007 | Breast cancer | — | IHC | — | Correlation with invasive ductal carcinoma and reduced T-lymphocytes infiltration |
|
| Kryczek et al. [9] | Cancer Res | 2007 | Ovarian carcinoma | 103 | IHC | — | Correlation with Treg cell numbers |
|
| Miyatake et al. [34] | Gynecol Oncol | 2007 | Uterine endometrioid adenocarcinoma | 90 | IHC, WB | 100% | Correlation with high risk of uterine endometrioid adenocarcinoma; reverse correlation with T-cell infiltration |
|
| Simon et al. [35] | Gynecol Oncol | 2007 | Ovarian cancer | 251 | ELISA | 48% (Stage I) 55% (Stage II)
67% (Stage III) | Correlation with poor prognosis |
|
| Simon et al. [36] | Gynecol Oncol | 2007 | Ovarian cancer | 68 | ELISA | 100% | A promising marker for early detection of ovarian cancer |
|
| Zang X et al. [5] | Proc Natl Acad SCI USA | 2007 | Prostate cancer | 823 | IHC | 99% | Associated with disease spread and poor outcome; an attractive targets for therapeutic manipulation |
|
| Sadun et al. [41] | Clin Cancer Res | 2007 | Breast and colorectal cancers | 8 (breast), 11 (colorectal) | RT-PCR | 100% (breast)
Not consistent | A potential therapeutic target |
|
| Krambeck et al. [12] | Proc Natl Acad SCI USA | 2006 | Renal cell carcinoma | 259 | IHC | 59.1% | B7-H4 is a useful prognostic marker for RRC patients |
|
| Sun et al. [8] | Lung Cancer | 2006 | Non-small-cell lung cancer | 70 | IHC | 43% | Correlation with lower number of T cell infiltration |
|
| Simon et al. [37] | Cancer Res | 2006 | Colon, breast, lung, prostate, and ovarian cancers | 1023 (confirmatory study : 200) | ELISA, IHC | — | Higher levels in endometrioid and serous histotypes than in mucinous histotypes in ovarian cancer |
|
| Tringler et al. [38] | Gynecol Oncol | 2006 | Ovarian cancer | 125 | IHC, WB | 9% (mucinous), 100% (other histotypes and metastases) | A potential diagnostic marker or therapeutic target for ovarian cancer |
|
| Bignotti et al. [23] | Gynecol Oncol | 2006 | Ovarian serous papillary carcinoma | 19 | Microarray | — | Among the most highly overexpressed genes, indicating that B7-H4 is a candidate biomarker for early screening |
|
| Scalceda et al. [19] | Exp Cell Res | 2005 | Breast and ovarian cancers | 19 (breast), 13 (ovarian) | RT-PCR, WB, IHC | 100% (breast), 53.8% (ovarian) | A potential therapeutic target |
|
| Tringler et al. [33] | Clin Cancer Res | 2005 | Breast cancer | 173 (primary), 246 (metastatic) | IHC | 95.4% (primary), 97.6% (metastatic) | Correlation with negative progesterone receptor and HER-2/neu status, history of chemotherapy; no correlation with grade, stage |
|
| Choi et al. [4] | J Immunol | 2003 | Ovarian and lung cancers | 22 (ovarian), 16 (lung ) | IHC | 85% (ovarian), 31% (lung) | A potential role in the evasion of tumor immunity |
|
